Drugs / Dianhydrogalactitol
Dianhydrogalactitol
also known as
VAL-083 · 1,2:5,6-dianhdrogalactitol · 1,2:5,6-dianhydrogalactitol · DAG · Dianhidrogalactitol · Dulcitol diepoxide · NSC-132313 · NSC-1323313
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03281681 | Mar 2021 → Mar 2022 | ovarian carcinoma | DelMar Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01478178 | Oct 2011 → Dec 2015 | brain cancer, glioblastoma | Kintara Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03050736 | Dec 2017 → Nov 2021 | brain cancer, glioblastoma | Kintara Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02717962 | Jan 2017 → Dec 2024 | brain cancer, glioblastoma | Kintara Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03149575 | Oct 2017 → May 2019 | brain cancer, glioblastoma | DelMar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03138629 Background | — | cancer | Kintara Therapeutics, Inc. | No longer available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dianhydrogalactitol | “provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency” NCT03138629 ↗5“Drug: VAL-083, Dianhydrogalactitol” NCT03281681 ↗ “VAL-083 (Dianhydrogalactitol)” NCT03050736 ↗ “VAL-083 (Dianhydrogalactitol)” NCT01478178 ↗ “VAL-083, Dianhydrogalactitol” NCT03149575 ↗ “VAL-083, Dianhydrogalactitol” NCT02717962 ↗ |
| Known as | 1,2:5,6-dianhdrogalactitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | 1,2:5,6-dianhydrogalactitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | DAG | “VAL-083 (dianhydrogalactitol; DAG) is a DNA-targeting agent” PMID 41385182 ↗ Dec 2025 |
| Known as | Dianhidrogalactitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | Dulcitol diepoxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | NSC-132313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | NSC-1323313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | VAL-083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03050736 ↗ |
| Modality | Other / unclassified | “The study drug, dianhydrogalactitol (VAL 083) is a bi-functional N7 DNA alkylating agent” NCT03050736 ↗ |
| Route | Intravenous | “given by intravenous infusion” NCT01478178 ↗ |